En el caso de un robot bípedo avanzado, suelen ser necesarios muchos sensores para que este sea capaz de mantener el equilibrio en tiempo real mientras avanza sobre un terreno. Depender tanto de los sensores hace vulnerable al robot a fallos en ellos, algo que puede ocurrir fácilmente …
En este Short os hablamos de un material muy especial que, al contrario que otros, absorbe más humedad cuando aumenta la temperatura exterior. …
VanDeMark Chemical, Inc., a leading global producer of life science chemistries, announced the appointment of Dr. Boudewijn van Lent as President and CEO, effective immediately.
Boudewijn van Lent Named President and CEO of VanDeMark Chemicals Read More »
KalVista Pharmaceuticals, Inc. announced that it made two oral presentations and one poster presentation at the 13th C1-inhibitor Deficiency & Angioedema Workshop in Budapest, Hungary.
Zomedica Corp., announced it has exercised its option to move forward with the acquisition of Structured Monitoring Products, Inc., the makers of VetGuardian™ zero-touch vital signs remote monitoring system, at a previously negotiated purchase price.
Zomedica Exercises Option to Acquire Structured Monitoring Products Read More »
Acorda Therapeutics, Inc. (Nasdaq: ACOR) and Hangzhou Chance Pharmaceuticals Co. Ltd. today announced that they have entered into distribution and supply agreements to provide INBRIJA ® in China.
Bruker Announces Acquisition of ZONTAL to Advance the Digital Laboratory Transformation and Integrated Biopharma Data Solutions.
Vedanta Biosciences today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to Vedanta’s defined bacterial consortium candidate, VE303, for the prevention of recurrent Clostridioides difficile infection (rCDI).
Bliss Biopharmaceutical Co., Ltd announced a clinical trial collaboration agreement with option for strategic collaboration with Eisai Co., Ltd., for BB-1701, eribulin-payload based ADC directed against Human Epidermal Growth Factor Receptor 2 for the treatment of cancers.
Innovent Biologics, Inc. announces that second interim analysis and survival analysis results of the ORIENT-31 study have been published in the Lancet Respiratory Medicine.
